Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
MORRISTOWN, N.J., April 05, 2016 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at Needham & Company’s 15th Annual Healthcare Conference, as follows.
| Date: | Wednesday, April 13, 2016 | |
| Time: | 3:00 PM EDT | |
| Location: | New York, NY - Westin New York Grand Central Hotel | |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Matthew P. Duffy, 212.915.0685 LifeSci Advisors, LLC [email protected]
